COAG financial statements
The full income statement, balance sheet, and cash-flow statement for Hemab Therapeutics Holdings Inc. (COAG), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
| Line item | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Income Statement | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 26.1M | 23.6M | ||
| Research & development | 20.3M | 19.5M | |
| Selling, general & administrative | 5.74M | 4.15M | |
| Operating income | -26.1M | -23.6M | |
| Pre-tax income | -24.1M | -22.7M | |
| Income tax | 97.0K | 12.0K | |
| Net income | -24.1M | -22.7M | |
| -$0.80 | -$23.98 | ||
| EPS (basic) | -$0.80 | -$23.98 | |
| Weighted-avg shares (basic) | 30.1M | 946K | |
| Weighted-avg shares (diluted) | 30.1M | 946K | |
| Balance Sheet | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 464M | 169M | ||
| Cash & equivalents | 237M | 49.9M | |
| Short-term investments | 220M | 114M | |
| Prepaid expenses | 6.54M | 5.90M | |
| 468M | 175M | ||
| Property, plant & equipment | 596K | 648K | |
| Operating lease right-of-use | 901K | 939K | |
| Other non-current assets | 2.29M | 4.24M | |
| 12.9M | 13.2M | ||
| Accounts payable | 6.23M | 5.68M | |
| Accrued liabilities | 6.25M | 6.96M | |
| Current lease liability | 460K | 544K | |
| Other current liabilities | 990K | 2.66M | |
| 13.5M | 13.7M | ||
| Non-current lease liability | 566K | 519K | |
| 454M | -199M | ||
| Additional paid-in capital | 686M | 6.37M | |
| Retained earnings | -229M | -205M | |
| Accumulated other comprehensive income | -2.75M | -439K | |
| Total equity incl. non-controlling | -454M | -199M | |
| Total liabilities & equity | 468M | 175M | |
| Shares outstanding (cover) | 46.7M | 46.7M | |
| Cash Flow | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| -22.6M | -21.6M | ||
| Depreciation & amortization | 75.0K | 73.0K | |
| Change in payables | 550K | -52.0K | |
| -107M | -15.8M | ||
| Capital expenditure | 23.0K | 112K | |
| Free cash flow | -22.7M | -21.7M | |
| Acquisitions | 0.00 | 0.00 | |
| 318M | -460K | ||
| Long-term debt issued | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | |
| Common stock issued | 317M | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | |
| Net change in cash | 188M | -38.1M | |
| Valuation Ratios | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| Market cap | 1.11B | — | |
| P/B | 2.4× | — | |
| Source filing | 10-Q | 10-Q |
About this data
Source: COAG’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all COAG filings on SEC EDGAR → Not investment advice.